Evaluation of various bioactive molecules for their gp120-CD4 binding inhibitory properties by in-silico molecular docking and dynamic studies.

Acquired immunodeficiency syndrome (AIDS), caused by the human immunodeficiency virus (HIV), remains a significant global health challenge, affecting over 38.4 million individuals worldwide according to the World Health Organization (WHO). The high mutation rate of HIV complicates the effectiveness of conventional antiviral drugs, necessitating novel therapeutic approaches.